ImageneBio Inc

NASDAQ:IMA

Biotechnology

Healthcare
$4.61 +6.06%

+$0.35 today

Market cap
$52.00M
Beta
0.72
P/E (TTM)
-1.5
EPS (TTM)
-$4.02
52W Low $3.94High $18.00

Volume 0.00M

Average 0.35M

IMA Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

ImageneBio IncNASDAQ: IMA

Gross Margin · Q1 FY2026 · quarter ended Mar 2026

Gross margin not reported for Q1 FY2026

Over 3 fiscal years it widened by 282.7 pp.

Context

  • Gross margin widened in 2 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
—— QoQ
Last fiscal yearDec 2025
-29.1%-129.1 pp YoY
LTMMar 2026
—— YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter———
1 year-129.1 pp——
3 years+282.7 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
-29.1%
Year-over-year change
-129.1pp

Gross Margin vs competitors

How IMA compares with its peers on the latest reported figures

  • IMA's FY2025 gross margin of -29.1% is the 4th highest of the 6 companies compared; the peer median is 98.7%.
  • Its year-over-year change of -129.1 pp is the 5th highest of 6, against a peer median of -0.5 pp.
  • Over three fiscal years its change of +282.7 pp compares with a peer median of +5.1 pp.
IMA Competitors Peer median
Gross Margin for IMA and competitors
Company Period LTM level YoY 3-year change
CNTBConnect Biopharma Holdings LimitedFY2025100.0% +0.0 pp—
OVIDOvid Therapeutics Inc.LTM Mar 202699.5% -0.5 pp-4.1 pp
STROSutro Biopharma, Inc.LTM Mar 202698.7% +1.4 pp+5.1 pp
IMAImageneBio IncFY2025-29.1% -129.1 pp+282.7 pp
STTKShattuck Labs, Inc.LTM Mar 2026-82.0% -120.1 pp+12607.2 pp
IFRXInflaRx N.V.LTM Mar 2026-24646.3% -22352.6 pp—
ARTVArtiva Biotherapeutics, Inc.FY2025— ——
KLRSKalaris Therapeutics IncFY2025— ——
CNTXContext Therapeutics Inc.FY2025— ——
Peer median (excluding IMA) 98.7%-0.5 pp+5.1 pp

Competitors are the stored peer set for IMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue30.99M15.62M9.16M3.5M800K
Cost of Revenue47.11M64.32M1.02M1.53M1.03M
Gross Profit(16.12M)(48.7M)8.14M3.5M(233K)
Gross Margin-52.0%-311.8%88.9%100.0%-29.1%
Research & Development47.11M64.32M59.65M32.11M28.53M
Selling, General & Admin18.02M22.2M24.93M8.39M20.73M
Operating Expenses18.02M22.2M83.56M40.5M48.22M
Depreciation & Amortization544K751K1.02M1.53M1.03M
EBITDA(33.57M)(68.01M)(67.31M)(35.03M)(44.67M)
EBITDA Margin-108.3%-435.5%-734.8%-1000.8%-5583.3%
Operating Income(34.14M)(70.9M)(75.42M)(37M)(48.45M)
Operating Margin-110.2%-454.0%-823.3%-1057.1%-6056.4%
Interest Income23K2.15M7.11M7.37M2.04M
Interest Expense00000
Other Income / Expenses23K2.14M7.09M445K2.75M
Income Before Tax(34.12M)(68.77M)(68.33M)(36.56M)(45.7M)
Pre-Tax Margin-110.1%-440.3%-745.9%-1044.4%-5712.4%
Income Tax Expense00(162K)13K(350K)
Net Income(34.12M)(68.77M)(68.17M)(36.57M)(45.35M)
Net Margin-110.1%-440.3%-744.2%-1044.8%-5668.6%
EPS (Basic)(0.95)(1.90)(1.63)(1.02)(10.76)
EPS (Diluted)(0.95)(1.90)(1.63)(1.02)(10.76)
Weighted Avg Shares35.98M36.19M41.74M48.26M4.87M
Weighted Avg Shares (Diluted)35.98M36.19M41.74M48.26M4.87M

ImageneBio Inc

NASDAQ:IMA

Intrinsic Alpha fair value

Locked

Current Price

$4.61

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.